Recent Updates
Recently added Catalysts
SRRK Positive Sentiment

Scholar Rock to Present at the 2019 Jefferies London Healthcare Conference

Key Takeaway: Scholar Rock Holding Corporation will present at the 2019 Jefferies London Healthcare Conference on November 20, 2019. The presentation will focus on the company's innovative approach to treating serious diseases through the development of monoclonal antibodies targeting protein growth factors. A live webcast will be available, with an archived replay accessible for 90 days post-event.

Market Sentiment Analysis

POSITIVE FACTORS

  • Scholar Rock is presenting at a notable healthcare conference.
  • The company is focused on innovative treatments for serious diseases.
  • They have a proprietary platform for developing monoclonal antibodies.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+68%
120-day peak, hindsight
Typical move
8.7%
average across 5 past catalysts
Cash runway
~21 mo
Low dilution risk
Lead asset
Apitegromab
Phase 3 · Spinal Muscular Atrophy

Full Press Release Details

CAMBRIDGE, Mass., Nov. 08, 2019 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that management will present at the 2019 Jefferies London Healthcare Conference on November 20, 2019 at 6:00 pm GMT (2:00 pm ET)
A live webcast of the presentation may be accessed by visiting the Investors & Media section of the Scholar Rock website athttp://investors.scholarrock.com.  An archived replay of the webcast will be available on the Company’s website for approximately 90 days following the presentation.
About Scholar RockScholar Rockis a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role.  Scholar Rock is creating a pipeline of novel product candidates with the potential to transform the lives of patients suffering from a wide range of serious diseases, including neuromuscular disorders, cancer, fibrosis and anemia.  Scholar Rock’s newly elucidated understanding of the molecular mechanisms of growth factor activation enabled it to develop aproprietary platformfor the discovery and development of monoclonal antibodies that locally and selectively target these signaling proteins at the cellular level.  By developing product candidates that act in the disease microenvironment, the Company intends to avoid the historical challenges associated with inhibiting growth factors for therapeutic effect.  Scholar Rock believes its focus on biologically validated growth factors may facilitate a more efficient development path.  For more information, please visitwww.ScholarRock.comor follow Scholar Rock on Twitter (@ScholarRock) and LinkedIn (https://www.linkedin.com/company/scholar-rock/).Scholar Rock® is a registered trademark of Scholar Rock, Inc.
Scholar Rock Contact:Investors/MediaCatherine Huchu@scholarrock.com917-601-1649Media Contact:The Yates NetworkKathryn Morriskathryn@theyatesnetwork.com914-204-6412

Frequently Asked Questions

When is Scholar Rock's presentation at the conference?

Scholar Rock will present on November 20, 2019, at 6:00 pm GMT.

How can I access the presentation webcast?

The live webcast can be accessed via the Investors & Media section of Scholar Rock's website.

What is Scholar Rock focused on?

Scholar Rock focuses on developing innovative medicines for serious diseases involving protein growth factors.

What is the duration of the archived webcast?

The archived replay of the webcast will be available for approximately 90 days.

Last updated: Nov 8, 2019